Agilent Technologies, Inc. has recently released its 10-Q report, providing a detailed overview of its operations and financial performance. The company, incorporated in 1999 and headquartered in Santa Clara, California, operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. It offers a wide range of solutions including instruments, software, services, and consumables for the entire laboratory workflow, catering to the life sciences, diagnostics, and applied chemical markets globally.
In the 10-Q report, Agilent Technologies, Inc. reported net revenue of $1,738 million and $5,087 million for the three and nine months ended July 31, 2025, marking a 10 percent and 6 percent increase, respectively, compared to the same periods last year. The company noted that the overall effect of foreign currency movements on revenue growth had a 2 percentage point favorable impact for the three months ended July 31, 2025. However, net income for the three and nine months ended July 31, 2025, was $336 million and $869 million, respectively, compared to net income of $282 million and $938 million for the corresponding periods last year. Cash provided by operations in the nine months ended July 31, 2025, was $1,014 million, compared to $1,270 million in the same period last year.
During the three and nine months ended July 31, 2025, Agilent Technologies, Inc. paid cash dividends of $0.248 per common share or $71 million and $0.744 per common share or $212 million, respectively, on the company's common stock. The company also repurchased and retired 737,474 shares for $85 million and 2.734 million shares for $340 million, respectively, under its 2023 repurchase program.
The report also highlighted the company's restructuring plans, with a focus on optimizing its management structure to better serve customers. In the second quarter of fiscal year 2025, Agilent announced a restructuring plan, with estimated annual cost savings of approximately $75 million to $80 million across its three business segments. The restructuring expense associated with this plan amounted to approximately $17 million and $73 million in the three and nine months ended July 31, 2025, respectively.
As a result of these announcements, the company's shares have moved 0.32% on the market, and are now trading at a price of $125.36. For more information, read the company's full 10-Q submission here.
